M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Post navigation Previous: Novo’s CEO champions “record-breaking start” for Wegovy pill in US marketNext: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026